Coya Therapeutics is a clinical-stage biotechnology company focused on developing therapies to improve the function of regulatory T cells ("Tregs"). Tregs consist of CD4+CD25high hFOXP3+ cells, which are a subpopulation of T-lymphocytes. Co. has product candidate pipeline that includes both ex vivo and in vivo therapeutic approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Co.'s product candidate pipeline is based on: Treg-enhancing biologics; Treg-derived exosomes (a sac-like structures that are formed inside a cell and contain some of the cell's proteins, lipids, and nucleic acids); and autologous (obtained from the same individual) Treg cell therapy. The COYA average annual return since 2022 is shown above.
The Average Annual Return on the COYA average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether COYA average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the COYA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|